SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"20877517"
 

Sökning: onr:"20877517" > Long-term safety of...

Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency a phase 3b, open-label, extension study

Nilsson, Anna G. (författare)
Bergthorsdottir, Ragnhildur (författare)
Burman, Pia (författare)
visa fler...
Dahlqvist, Per (författare)
Ekman, Bertil (författare)
Engstrom, Britt Eden (författare)
Ragnarsson, Oskar (författare)
Skrtic, Stanko (författare)
Wahlberg, Jeanette (författare)
Achenbach, Heinrich (författare)
Uddin, Sharif (författare)
Marelli, Claudio (författare)
Johannsson, Gudmundur (författare)
visa färre...
 (utgivare)
2017
2017
Engelska.
Ingår i: European Journal of Endocrinology. - 0804-4643. ; 176:6, 715-725
  • swepub:Mat__t
Abstract Ämnesord
Stäng  
  • Objective: To investigate the long-term safety and tolerability of a once-daily, dual-release hydrocortisone (DR-HC) tablet as oral glucocorticoid replacement therapy in patients with primary adrenal insufficiency (AI). Design: Prospective, open-label, multicenter, 5-year extension study of DR-HC conducted at five university clinics in Sweden. Methods: Seventy-one adult patients diagnosed with primary AI who were receiving stable glucocorticoid replacement therapy were recruited. Safety and tolerability outcomes included adverse events (AEs), intercurrent illness episodes, laboratory parameters and vital signs. Quality of life (QoL) was evaluated using generic questionnaires. Results: Total DR-HC exposure was 328 patient-treatment years. Seventy patients reported 1060 AEs (323 per 100 patient-years); 85% were considered unrelated to DR-HC by the investigator. The most common AEs were nasopharyngitis (70%), fatigue (52%) and gastroenteritis (48%). Of 65 serious AEs reported by 32 patients (20 per 100 patient-years), four were considered to be possibly related to DR-HC: acute AI ( n  = 2), gastritis ( n  = 1) and syncope ( n  = 1). Two deaths were reported (fall from height and subarachnoid hemorrhage), both considered to be unrelated to DR-HC. From baseline to 5 years, intercurrent illness episodes remained relatively stable (mean 2.6–5.4 episodes per patient per year), fasting plasma glucose (0.7 mmol/L;  P  < 0.0001) and HDL cholesterol (0.2 mmol/L;  P  < 0.0001) increased and patient-/investigator-assessed tolerability improved. QoL total scores were unchanged but worsening physical functioning was recorded ( P  = 0.008). Conclusions: In the first prospective study evaluating the long-term safety of glucocorticoid replacement therapy in patients with primary AI, DR-HC was well tolerated with no safety concerns observed during 5-year treatment.

Ämnesord

Medical and Health Sciences  (hsv)
Clinical Medicine  (hsv)
Family Medicine  (hsv)
Medicin och hälsovetenskap  (hsv)
Klinisk medicin  (hsv)
Allmän medicin  (hsv)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy